BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1760927)

  • 1. Clinical use of tumor markers in oncology.
    Jacobs EL; Haskell CM
    Curr Probl Cancer; 1991; 15(6):299-360. PubMed ID: 1760927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor markers: value and limitations in the management of cancer patients.
    Bates SE; Longo DL
    Cancer Treat Rev; 1985 Sep; 12(3):163-207. PubMed ID: 2416441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical usefulness of circulating tumor markers].
    Ohkura H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers.
    Desai S; Guddati AK
    World J Oncol; 2023 Feb; 14(1):4-14. PubMed ID: 36895994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers and characteristics of human SCLC cell lines. Neuroendocrine markers, classical tumor markers, and chromosomal characteristics of permanent human small cell lung cancer cell lines.
    Bepler G; Jaques G; Koehler A; Gropp C; Havemann K
    J Cancer Res Clin Oncol; 1987; 113(3):253-9. PubMed ID: 2438285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sense and nonsense of tumor markers in practice].
    Joss R; Cerny T
    Schweiz Med Wochenschr; 1990 May; 120(19):693-703. PubMed ID: 1693445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical evaluation of human esophageal neoplasms and preneoplastic lesions for beta-chorionic gonadotropin, placental lactogen, alpha-fetoprotein, carcinoembryonic antigen, and nonspecific cross-reacting antigen.
    Burg-Kurland CL; Purnell DM; Combs JW; Hillman EA; Harris CC; Trump BF
    Cancer Res; 1986 Jun; 46(6):2936-43. PubMed ID: 2421889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of placental alkaline phosphatase (PLAP) in the monitoring of patients with seminoma.
    Koshida K; Uchibayashi T; Yamamoto H; Hirano K
    Br J Urol; 1996 Jan; 77(1):138-42. PubMed ID: 8653285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
    Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
    Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
    Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M
    Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of tumour markers.
    Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
    Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
    Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
    Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of seminoma tissue markers and deletions.
    Yamamoto H; Rudén U; Ljungdahl-Ståhle E; Brehmer-Andersson E; Hirano K; Hisazumi H; Stigbrand T; Wahren B
    Int J Cancer; 1987 Nov; 40(5):615-9. PubMed ID: 2445700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical relevance of tumor markers].
    Lamerz R
    Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in patients with chronic renal failure.
    Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
    Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
    Tarle M; Radoś N
    Prostate; 1991; 19(1):23-33. PubMed ID: 1715080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects.
    Sisinni L; Landriscina M
    Adv Exp Med Biol; 2015; 867():159-76. PubMed ID: 26530366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of multiple tumor markers's protein chip in the screen program of the elderly].
    Yan HY; Zhong RH; Li J; Luo XH; Chen R
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Sep; 32(9):924-6. PubMed ID: 22340884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.